He holds a BS degree in marketing from LaSalle University, Philadelphia, and an MBA degree from St. Joseph's University, Philadelphia. "I am excited to take on the role of interim CEO of BioSpecifics," Truiit says. "There are very significant value creation opportunities and I look forward to working closely with the board of directors and team to fully execute on the company's clearly defined corporate objectives." BioSpecifics discovered and developed a proprietary form of injectable collagenase which is marketed by BioSpecifics' partner, Endo International plc, as Xiaflex in North America for the treatment of Dupuytren's contracture and Peyronie's disease.